News

Xequel Bio Expands Leadership Team with Appointments of Dr. Michael J. Brubaker as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer

Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 – Xequel Bio, Inc., a clinical stage biopharmaceutical company developing dermatologic and ophthalmic therapeutics utilizing its patented new chemical entity aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide), announced today the appointments of Michael...

Xequel Bio Announces Positive Results from Phase 1b Study of iNexinTM, a Novel aCT1 Ophthalmic Solution

Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance to Phase 2 Proprietary aCT1 Platform to Address Unmet Needs for Patients with Ophthalmic Diseases Charleston, SCand Fort Worth, TX, July 14, 2022 --Xequel Bio, Inc., a clinical stage biopharmaceutical...

Xequel Bio, Inc. Appoints Veteran Pharmaceutical Executives to Advance Next Stage of Corporate Growth

Jerry St. Peter Named Chief Executive Officer and Member of the Board of Directors Wes Brazell Named Chief Financial Officer Executives Bring Significant Global Biopharmaceutical Development and Commercial Expertise New Corporate Name Launches Strategic Evolution to Late-Stage Development Charleston, SC and Fort Worth, TX, May 11, 2022 -- Xequel Bio,...